GLP1R and fatty liver disease: Although hepatocytes do not directly express GLP-1 receptors, there is overwhelming evidence to suggest that the use of GLP-1 receptor agonists (GLP-1RA; e.g., semaglutide) is correlated with improved hepatic steatosis and slowing of fibrosis [33,34,35,36,37].